Akebia Therapeutics, Inc. (AKBA) vs Henry Schein, Inc. (HSIC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AKBA | HSIC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Medical Distribution |
| Size band | SMALL | MID |
| Listing | Nasdaq CM | Nasdaq GS |
| Country | United States | United States |
| Theme | rare-disease | dental-care |
| Price and returns | ||
| Last close | $0.64 | $84.51 |
| Return · 1 week | −5.32% | +0.64% |
| Return · 1 month | −27.91% | −1.72% |
| Return · 3 months | −49.31% | −1.40% |
| Return · year to date | −58.46% | +10.01% |
| Return · 1 year | −79.69% | +33.00% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −79.88% | −8.32% |
| 52-week high | $3.20 | $92.18 |
| 52-week low | $0.54 | $62.15 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $178.40M | $9.63B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $4.77M | $86.83M |
| Employees | 194 | 25,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 24.77× |
| Price to earnings · forward | n/a (negative forward earnings) | 14.17× |
| Price to sales | 1.01× | 0.71× |
| Price to book | 8.71× | 3.01× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 13.60× |
| Enterprise value to revenue | 1.30× | 1.08× |
| PEG ratio | — | 1.69 |
| Earnings per share · trailing | -0.12 | 3.43 |
| Profitability | ||
| Gross margin | 79.63% | 31.32% |
| Operating margin | −5.46% | 5.76% |
| Profit margin | −13.54% | 2.96% |
| Return on equity | −109.38% | 8.85% |
| Return on assets | −1.05% | 4.39% |
| Growth | ||
| Revenue growth | −21.40% | +6.70% |
| Earnings growth | — | +17.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 796.18 | 80.73 |
| Current ratio | 1.43 | 1.32 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | — | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 35.08 | 45.66 |
| ADX · 14 | 33.65 | 18.77 |
| 50-day average | $0.86 | $86.85 |
| 200-day average | $1.16 | $80.89 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 8.40% | 2.39% |
The full AKBA analysis
Everything this table leaves out for Akebia Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AKBA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AKBA analysisThe full HSIC analysis
Everything this table leaves out for Henry Schein, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HSIC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HSIC analysis